{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-023903","form_type":"8-K/A","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2026-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.401099+00:00","generated_at":"2026-05-15T07:19:10.718018+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Skye Bioscience amends 8-K to correct option repricing share count to 2,458,158","bullets":["Amendment corrects a scrivener's error: total shares underlying Repriced Options is 2,458,158.","No other changes to the original April 3, 2026 8-K filing on compensatory arrangements.","CEO Punit Dhillon signed the amendment dated April 6, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-023903","json":"https://secwatch.observer/filing/0001628280-26-023903.json","markdown":"https://secwatch.observer/filing/0001628280-26-023903.md","text":"https://secwatch.observer/filing/0001628280-26-023903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026023903/0001628280-26-023903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026023903/skye-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:19:10.718018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}